Cascades' second-quarter financial results surpassed forecasts, driven by enhanced operational efficiency, increased sales volumes, and strategic commercial initiatives across both its packaging and tissue divisions. The company saw substantial growth in its key segments, leading to improved profitability and cash flow. Despite an uncertain global economic landscape, Cascades' management expressed confidence in its ability to navigate challenges and sustain positive momentum. The company projects continued sequential growth into the third quarter and aims for a robust annual adjusted EBITDA run rate of over CAD 600 million by the latter half of 2026. Furthermore, Cascades is proactively evaluating the potential ramifications of newly imposed U.S. tariffs, devising mitigation strategies to minimize any adverse effects on its financial performance.

The company demonstrated strong financial health with a notable reduction in net debt, primarily due to robust operating cash flow. Strategic asset monetizations and credit facility extensions also underscore Cascades' prudent financial management and its commitment to long-term stability. While facing increased raw material and transportation costs, effective cost management and pricing adjustments have allowed Cascades to maintain a positive trajectory. The company's focus on optimizing its manufacturing base for conventional tissue products and its ongoing profitability improvement program are expected to further bolster its financial standing and market position.

Packaging Segment's Resilient Growth and Strategic Initiatives

Cascades' packaging division reported a strong sequential upturn in the second quarter, recording sales of CAD 772 million, an 8% increase from the previous period. This growth was complemented by a 16% rise in adjusted EBITDA, reaching CAD 120 million, and an improved EBITDA margin of 15.5%. These positive results stem from higher sales volumes, enhanced pricing strategies, and significant improvements in manufacturing operations. The company's total packaging shipments saw a 9% sequential increase, with box shipments and external paper shipments contributing substantially to this growth. Cascades' performance in box shipments notably outpaced the industry average, underscoring its competitive strength and effective market penetration. Record production levels at key facilities like Greenpac and Bear Island further highlight the segment's operational excellence and capacity utilization.

The sustained robust demand for paper rolls, exceeding current shipping capabilities, indicates a strong market position for Cascades' packaging products. To capitalize on this demand, the company announced further price adjustments for linerboard and white paper grades, and medium, effective in the upcoming quarter. These pricing initiatives are expected to positively impact fourth-quarter earnings. A significant portion of Cascades' box customers are under contractual agreements tied to linerboard prices, providing a stable revenue stream. The company's strategic focus on operational improvements and commercial initiatives has clearly paid dividends, positioning the packaging segment for continued success despite potential market fluctuations and increasing input costs. The ability to increase shipments and maintain favorable pricing demonstrates effective management and a strong market foothold.

Tissue Segment Performance, Cost Management, and Future Outlook

The tissue segment of Cascades also demonstrated solid performance in the second quarter, with sales climbing 7.6% sequentially to CAD 409 million, and adjusted EBITDA increasing by 6% to CAD 35 million. Despite the segment's EBITDA margin remaining consistent at 8.6%, the positive results were driven by higher sales volumes and a more advantageous product mix. However, these gains were partially offset by rising raw material and transportation expenses. Total tissue shipments increased by 7% sequentially, with notable growth in both retail and away-from-home volumes, reflecting successful commercial strategies and strong consumer demand. While year-over-year adjusted EBITDA saw a slight decline due to increased logistics costs, the company effectively mitigated these impacts through volume growth, pricing adjustments, and cost-saving initiatives.

Cascades remains committed to its role as a leading supplier of private-brand tissue products, prioritizing the optimization of its conventional tissue manufacturing base over investing in new advanced technologies like through-air-dried (TAD) machines. This strategic approach aligns with the company's belief in the continued relevance of conventional tissue products. Looking ahead, Cascades anticipates further sequential improvements in its consolidated results for the third quarter, driven by seasonal demand and ongoing pricing initiatives. The company's profitability improvement program, which has already yielded significant benefits in previous years, is expected to continue contributing to its financial targets. Management is also actively evaluating the implications of potential U.S. tariffs, with plans to implement mitigation measures such as shifting production between Canadian and U.S. facilities to limit any adverse impact on its adjusted EBITDA. These proactive steps, coupled with successful asset monetizations and extended credit facilities, underscore Cascades' resilient financial strategy and its optimistic outlook for sustained growth.